CERo Therapeutics Holdings (CERo Therapeutics Holdings) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings ROE % Adjusted to Book Value?

CERo Therapeutics Holdings's ROE % for the quarter that ended in Dec. 2022 was 0.00%. CERo Therapeutics Holdings's PB Ratio for the quarter that ended in Dec. 2022 was N/A. CERo Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was N/A.

CERo Therapeutics Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for CERo Therapeutics Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings ROE % Adjusted to Book Value Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

ROE % Adjusted to Book Value

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
ROE % Adjusted to Book Value	-	-

Competitive Comparison of CERo Therapeutics Holdings's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CERo Therapeutics Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CERo Therapeutics Holdings's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's ROE % Adjusted to Book Value falls into.

CERo Therapeutics Holdings ROE % Adjusted to Book Value Calculation

CERo Therapeutics Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

CERo Therapeutics Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

CERo Therapeutics Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024